RNF5 and cystic fibrosis: While RMA1 and RNF185 readily target both wild-type and F508del CFTR intermediates for degradation [49,120], RMA1 ablation more prominently improves F508del CFTR maturation and can partially alleviate a CF phenotype in mice, even without additional therapeutic interventions [126].